Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie — Clinical Trial Site

73 Registered trials

36 Currently recruiting

Organisation

Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie

Location

Olsztyn, Poland

Identifier

ORG-100045165

Address

Ul. Jagiellonska Nr 78, 10-357, Poland

Departments

-
#5705 Oddzial Onkologii z Pododdzialem Chemioterapii
5701: Oddzial Onkologii z Pododdzialem Chemioterapii
5705: Oddział Onkologii z Pododdziałem Chemioterapii
Klinika Pulmonologii
N/A
NA
NA Oddział Onkologii z Pododdziałem Chemioterapii
Oddzal Onkologii z Pododdzialem Chemioterapii
Oddzial onkologii z pododdziałem chemioterapii
Oddzial onkologii z poddodzialem chemioterapii
Oddzial Onkologii z Pododdzialem Chemioterapii
Oddzial Onkologii z Pododdziałem Chemioterapii
Oddzial Onkologii z Pododzialem Chemioterapii
Oddział Alergologiczno-Pulmonologiczny
Oddział Onkologii
Oddział Onkologii i pododdziałem chemioterapii
Oddział Onkologii z Pododdziałem Chemioterapii
Oddział Onkologii z Pododdziałem Chemioterapii
Oddział Onkologii z PododdziałemChemioterapii
Oddział Onkologii z Pododziałem Chemioterapii
Oddziatu Onkologii z Pododdziatem Chemioterapi
Oncology
Oncology Department with Chemotherapy Sub-Division
Szpital Pulmonologiczny, Oddzial Onkologii z Pododdzialem Chemioterapii

Clinical trials at this site (73)

Search interface

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of NSCLC Recruiting

2024-519883-42-00 Non-small cell lung cancer 5 2025-10-08
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad… Recruiting

2023-509883-89-00 Epidermal growth factor receptor (EGFR) mutation-positi 5 2025-01-09
Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting

2024-514304-14-00 Advanced or Metastatic Non-squamous Non-Small Cell Lung 1 2024-10-08
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 5 2024-03-20
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Extensive Stage Small Cell Lung Cancer 5 2023-09-27
A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici… Recruiting

2023-507171-22-00 Untreated Advanced or Metastatic Non-Small Cell Lung Ca 9 2023-06-21
Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced n… Recruiting

2023-509283-14-00 Advanced non-small cell lung cancer 1 2022-04-25
A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemo… Recruiting

2023-504949-31-00 Advanced or metastatic non-squamous non-small lung canc 3 2021-12-01
Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Pan tumor 4 2020-05-05
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab… Ended

2022-502954-15-00 Idiopathic pulmonary fibrosis 4 2024-06-21
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Ended

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
Clinical Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) versus Intravenous Pembrolizumab, Given with Chemoth… Ended

2022-501506-36-00 First-line treatment of participants with metastatic no 5 2023-04-11
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c… Ended

2024-511169-12-00 Non-Small Cell Lung Cancer 5 2023-03-28
A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05